Next Article in Journal
Spatial and Genomic Correlates of HIV-1 Integration Site Targeting
Next Article in Special Issue
Identification of Dysregulated Expression of G Protein Coupled Receptors in Endocrine Tumors by Bioinformatics Analysis: Potential Drug Targets?
Previous Article in Journal
The RAF Kinase Inhibitor Protein (RKIP): Good as Tumour Suppressor, Bad for the Heart
Previous Article in Special Issue
Expression of Proton-Sensitive GPR31, GPR151, TASK1 and TASK3 in Common Skin Tumors
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

C-C Chemokine Receptor 7 in Cancer

by
Colin A. Bill
,
Christopher M. Allen
and
Charlotte M. Vines
*
Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA
*
Author to whom correspondence should be addressed.
Cells 2022, 11(4), 656; https://doi.org/10.3390/cells11040656
Submission received: 8 January 2022 / Revised: 1 February 2022 / Accepted: 8 February 2022 / Published: 14 February 2022
(This article belongs to the Special Issue G-Protein Coupled Receptors in Cancer)

Abstract

C-C chemokine receptor 7 (CCR7) was one of the first two chemokine receptors that were found to be upregulated in breast cancers. Chemokine receptors promote chemotaxis of cells and tissue organization. Since under homeostatic conditions, CCR7 promotes migration of immune cells to lymph nodes, questions immediately arose regarding the ability of CCR7 to direct migration of cancer cells to lymph nodes. The literature since 2000 was examined to determine to what extent the expression of CCR7 in malignant tumors promoted migration to the lymph nodes. The data indicated that in different cancers, CCR7 plays distinct roles in directing cells to lymph nodes, the skin or to the central nervous system. In certain tumors, it may even serve a protective role. Future studies should focus on defining mechanisms that differentially regulate the unfavorable or beneficial role that CCR7 plays in cancer pathophysiology, to be able to improve outcomes in patients who harbor CCR7-positive cancers.
Keywords: cancer; survival; metastases; C-C chemokine receptor 7 cancer; survival; metastases; C-C chemokine receptor 7
Graphical Abstract

Share and Cite

MDPI and ACS Style

Bill, C.A.; Allen, C.M.; Vines, C.M. C-C Chemokine Receptor 7 in Cancer. Cells 2022, 11, 656. https://doi.org/10.3390/cells11040656

AMA Style

Bill CA, Allen CM, Vines CM. C-C Chemokine Receptor 7 in Cancer. Cells. 2022; 11(4):656. https://doi.org/10.3390/cells11040656

Chicago/Turabian Style

Bill, Colin A., Christopher M. Allen, and Charlotte M. Vines. 2022. "C-C Chemokine Receptor 7 in Cancer" Cells 11, no. 4: 656. https://doi.org/10.3390/cells11040656

APA Style

Bill, C. A., Allen, C. M., & Vines, C. M. (2022). C-C Chemokine Receptor 7 in Cancer. Cells, 11(4), 656. https://doi.org/10.3390/cells11040656

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop